PSA, PCA3 and the phi losophy of prostate cancer management

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 4, 2013, Pages 707-712

  Melichar, Bohuslav ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ANDROGEN RECEPTOR; CARBAZITAXEL; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHYMOTRYPSIN INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; GAMMA INTERFERON; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GUANOSINE; NEOPTERIN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; SIGNAL PEPTIDE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; AUTOIMMUNE DISEASE; BLOOD; BLOOD LEVEL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALIGNANT ASCITES; MALIGNANT TRANSFORMATION; META ANALYSIS (TOPIC); OVARY CARCINOMA; PATHOGENESIS; PHILOSOPHY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEINURIA; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANTIGENS, NEOPLASM; DIABETIC NEUROPATHIES; FEMALE; HUMANS; IMMUNOASSAY; KIDNEY DISEASES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84882246985     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0156     Document Type: Review

References (49)

1. Melichar B, Plebani M. Laboratory medicine: an essential partner in the care of cancer patients. Clin Chem Lab Med 2011;49:1575-8.
2. Melichar B. Tumor biomarkers: PSA and beyond. Clin Chem Lab Med 2012;50:1865-9.
3. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32.
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
5. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
7. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:151-20.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
9. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
10. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
11. Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med 2012;50:1877-91.
12. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59:797-802.
13. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem 2012;393:301-17.
14. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008;54:1951-60.
15. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007;43:1918-26.
16. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Petterson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493-8.
17. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.
18. Filella X, Gimenez N. Evaluation of (-2) proPSA and prostate health index (phi) for the detection of prostate cancer: a systemic review and meta-analysis. Clin Chem Lab Med 2013;51:729-39.
19. Fischer K, Theil G, Hoda R, Fornara P. Missing agreement between the two IMMULITE PSA assays. Clin Chem Lab Med 2013;51:e37-e9.
20. Vucetic Z, Dnistrian A, Nilsson O, Lilja HG, Plebani M. Suitability of quality control materials for prostate-specific antigen (PSA) measurement: inter-method variability of common tumor marker control materials. Clin Chem Lab Med 2013;51:873-80.
21. Neves AF, Dias-Oliveira DD, Araujo TG, Marangoni K, Goulart LR. Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis. Clin Chem Lab Med 2013;51:881-87.
22. Turgutalp K, Ozhan O, Helvaci I, Ata A, Arican A, Boztepe B, et al. Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study. Clin Chem Lab Med 2013;51:889-95.
23. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precusor PSA (proPSA) isoforms: a review of the emerging role of pro PSAs in the detection and management of early prostate cancer. BJUI Int 2012 (in press).
24. Trape J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer A, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605-20.
25. Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2011;49:443-5.
26. Melichar B. Human epididymis protein 4: the start of a post-ROMAn era? Clin Chem Lab Med 2012;50:2069-73.
27. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgenregulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-61.
28. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-. J Natl Cancer Inst 2006;98:516-21.
29. Sella A, Sternberg CN, Skoneczna I, Kovel S. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int 2008;102:1607-9.
30. Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, et al. The postchemotherapy PSA surge syndrome. Ann Oncol 2008;19:1308-11.
31. Ulmert D, Vickers AJ, Scher HI, Becker C, Iversen P, Frankel D, et al. Rapid elimination kinetics of free PSA or human kallikreinrelated peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clin Chem Lab Med 2012;50:1993-8.
32. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4 + T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Inv 2001;61:363-70.
33. Melichar B, Jandik P, Krejsek J, Solichova D, Drahosova M, Skopec F, et al. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996;82:218-20.
34. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3 + tumor-infiltrating lymphocytes in ovarian carcinoma. Gyn Oncol 2008;108:415-20.
35. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 2008;26:1024-31.
36. Melichar B, Freedman RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 2002;12:3-17.
37. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003;13:435-43.
38. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and, immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 2003;9:5228-37.
39. Hammerer-Lercher A, Moser C, Leichtfried V, Schobersberger W, Griesmacher A, Fuchs D. Comparison of a commercial urinary neopterin radioimmunoassay with high performance liquid chromatography. Clin Chem Lab Med 2012;50:1075-8.
40. Moutereau S, Ech Chad N, Devanlay M, Esmilaire L, Loric S. Improved neopterin ELISA kit: a good compromise between HPLC results and clinical practice. Clin Chem Lab Med 2011;49:553-4.
41. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006; 16:240-52.
42. Melichar B, Gregor J, Solichova D, Lukes J, Tichy M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994;40:338-9.
43. Montagnana M, Lippi G, Danese E, Salvagno GL, Cervellin G, Guidi GC. Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I. Clin Chem Lab Med 2012;50:747-8.
44. Plata-Nazar K, Jankowska A. Clinical usefulness of determining the concentration of neopterin. Pteridines 2011;22:77-89.
45. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006;21:190-8.
46. Melichar B, Kalabova H, Krcmova L, Kasparova M, Plisek J, Cerman J, et al. Urinary neopterin in patients with metastatic colon cancer treated with patupilone. Pteridines 2011;22:61-5.
47. Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2009;55:1135-46.
48. Kralickova P, Kalabova H, Krcmova L, Kasparova M, Plisek J, Ungermann L, et al. Correlation of peripheral blood CD 14 + 16 + monocytes, urinary neopterin and the risk factors of atherosclerosis in patients with breast carcinoma. Pteridines 2011;22:66-2.
49. Aulitzky W, Frick J, Fuchs D, Hausen A, Reibnegger G, Wachter H. Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract. Cancer 1985;55:1052-5.